CSIMarket Company Name, Ticker, Suppliers, else..
 

Merrimack Pharmaceuticals Inc  (NASDAQ: MACK)

Merrimack Pharmaceuticals Inc's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

MACK Sales vs. its Competitors Q1 2024


Comparing the current results to its competitors, Merrimack Pharmaceuticals Inc reported Revenue decrease in the 1 quarter 2024 year on year by 0 %, despite the revenue increase by the most of its competitors of 9.13 %, recorded in the same quarter.

• List of MACK Competitors





Revenue Growth Comparisons




Net Income Comparison

Merrimack Pharmaceuticals Inc achieved net profit of $201.37 millions compared to a net loss of $-0.27 millions recorded in the same quarter a year ago.

<<  MACK Stock Performance Comparisons





*Market share is calculated based on total revenue.

  News about Merrimack Pharmaceuticals Inc Contracts

Merrimack Pharmaceuticals Receives Stockholder Approval for Dissolution Plan and Declares Cash Liquidating Dividend

May 12, 2024
 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK), a renowned biopharmaceutical company based in Cambridge, MA, recently announced that its stockholders have overwhelmingly approved the adoption of a Plan of Dissolution. Following this decision, the company s Board of Directors declared a liquidating cash dividend of $15.10 per share of common stock. This press release sheds light on the implications of the dissolution plan and its impact on Merrimack Pharmaceuticals and its stakeholders.Stockholders Approve Plan of DissolutionAt a Special Meeting held on date, Merrimack Pharmaceuticals stockholders gathered to vote on the adoption of a Plan of Dissolution. The plan garnered overwhelming support from the stock...





Publicly Traded Peers of Merrimack Pharmaceuticals Inc




Xilio Therapeutics Inc
Share Performance



-0.99%
Over The Past 5 Days
Xilio Therapeutics Inc
Profile

Xilio Therapeutics Inc is a biotechnology company focused on developing and commercializing novel immunotherapies to treat cancer.

More about Xilio Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 175.418 mill. $ 64.092 mill. $ -21.829 mill.


Myovant Sciences Ltd
Share Performance



+0.71%
This Quarter
Myovant Sciences Ltd
Profile

Myovant Sciences Ltd operates under a biopharmaceutical business model primarily focused on the development and commercialization of therapies for women's health and prostate cancer. The company aims to leverage its expertise in clinical research, regulatory affairs, and manufacturing to bring innovative treatments to market and improve patients' lives. Myovant Sciences employs a combination of in-house research and development along with collaboration with strategic partners to advance its pipeline of product candidates.

More about Myovant Sciences Ltd 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,613.259 mill. $ 379.112 mill. $ -183.770 mill.


Mirati Therapeutics Inc
Share Performance



+22.52%
One Year
Mirati Therapeutics Inc
Profile

Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.

More about Mirati Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 3,815.094 mill. $ 38.191 mill. $ -725.878 mill.


Morphosys Ag
Share Performance



+1.94%
Over The Past 5 Days
Morphosys Ag
Profile

Morphosys Ag's business model revolves around the development and commercialization of therapeutic antibodies.

More about Morphosys Ag's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 650.570 mill. $ 266.872 mill. $ -212.502 mill.


Monopar Therapeutics Inc
Share Performance



-11.65%
Over The Past 5 Days
Monopar Therapeutics Inc
Profile

Monopar Therapeutics Inc operates under a business model focused on developing and commercializing innovative therapeutics for the treatment of various cancers. The company aims to leverage strategic partnerships with academic institutions and other pharmaceutical companies to facilitate the development and distribution of their products.

More about Monopar Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 728.116 mill. $ - mill. $ -17.845 mill.

36 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Merrimack Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Merrimack Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.